#152482

Anti-CD29 [12G10]

Cat. #152482

Anti-CD29 [12G10]

Cat. #: 152482

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: CD29 (Integrin b1 chain)

Class: Monoclonal

Application: ELISA ; FACS ; IHC ; IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Martin Humphries

Institute: University of Manchester

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-CD29 [12G10]
  • Alternate name: Integrin Subunit Beta 1; Glycoprotein Iia; MSK12; GPIIA; FNRB; MDF2; Very Late Activation Protein; Beta Polypeptide; Fibronectin Receptor Subunit Beta; Integrin VLA-4 Beta Subunit; CD29 Antigen; VLA-BETA; CD29; VLAB
  • Clone: 12G10
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; FACS ; IHC ; IF ; IP ; WB
  • Description: CD29 is a member of the family of integrins, membrane receptors involved in cell adhesion and recognition in a variety of processes including embryogenesis, hemostasis, tissue repair, immune response and metastatic diffusion of tumor cells.
  • Immunogen: Purified human ?1 integrin preparation from HT1080 fibrosarcoma cell extract.
  • Isotype: IgG1
  • Myeloma used: P3X63Ag8.653

Target Details

  • Target: CD29 (Integrin b1 chain)
  • Target background: CD29 is a member of the family of integrins, membrane receptors involved in cell adhesion and recognition in a variety of processes including embryogenesis, hemostasis, tissue repair, immune response and metastatic diffusion of tumor cells.

Applications

  • Application: ELISA ; FACS ; IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Chen et al. 2009. PLoS One. 4(8):e6565. PMID: 19668337.
  • MMP7 shedding of syndecan-1 facilitates re-epithelialization by affecting alpha(2)beta(1) integrin activation.
  • Yamamoto et al. 2009. Endocrinology. 150(2):990-9. PMID: 18845630.
  • N-acetylglucosaminyltransferase V regulates extravillous trophoblast invasion through glycosylation of alpha5beta1 integrin.
  • Yamamoto et al. 2007. Br J Cancer. 97(11):1538-44. PMID: 17971775.
  • Expression of N-acetylglucosaminyltransferase V in endometrial cancer correlates with poor prognosis.
  • Cavallo-Medved et al. 2005. J Cell Sci. 118(Pt 7):1493-503. PMID: 15769846.
  • Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells.
  • Avizienyte et al. 2002. Nat Cell Biol. 4(8):632-8. PMID: 12134161.
  • Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling.
  • Iba et al. 2000. J Cell Biol. 149(5):1143-56. PMID: 10831617.
  • The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading.
  • Mould et al. 1998. Biochem J. 331 ( Pt 3):821-8. PMID: 9560310.
  • Regulation of integrin function: evidence that bivalent-cation-induced conformational changes lead to the unmasking of ligand-binding sites within integrin alpha5 beta1.
  • Mould et al. 1995. Biochem Soc Trans. 23(3):395S. PMID: 8566283.
  • Regulation of integrin alpha 5 beta 1 function by anti-integrin antibodies and divalent cations.
  • Mould et al. 1995. FEBS Lett. 363(1-2):118-22. PMID: 7537221.
  • Identification of a novel anti-integrin monoclonal antibody that recognises a ligand-induced binding site epitope on the beta 1 subunit.